Indian pharmaceutical and life sciences companies are rapidly transitioning from their traditional strength in generic medicines to innovation-led drug discovery, with patent filings quadrupling over the past decade and researchers discovering more than 10 novel drug molecules, according to a joint report by Boston Consulting Group (BCG) and HealthKois. The report highlights India’s growing role in global pharmaceutical innovation, supported by rising venture capital investments, government funding, and stronger research capabilities.
Titled “Built on Scale, Turning to Science: India’s Pharma and Life Sciences Innovation Opportunity,” the report says India’s pharmaceutical innovation pipeline has expanded 1.5 times to 1,095 active programmes across 195 companies, while private equity and venture capital investments in the sector have more than doubled to $731 million in FY26. These trends signal a structural shift from a generics-driven industry toward research-based drug discovery and advanced biotechnology.
India’s Pharmaceutical Innovation Gains Momentum
According to the BCG–HealthKois report:
- Pharmaceutical patent filings have increased more than fourfold over the last decade.
- India has discovered over 10 novel drug molecules.
- The country’s drug discovery pipeline has expanded significantly.
- Venture capital investment continues to rise as investors back innovation-focused companies.
Innovation Snapshot
| Metric | Latest Status |
|---|---|
| Active Drug Discovery Programmes | 1,095 |
| Companies Involved | 195 |
| Novel Drug Molecules Discovered | More than 10 |
| PE/VC Investment in FY26 | $731 million |
| Growth in Patent Families (2015–2024) | 716 to 2,995 |
Patent Filings Quadruple in a Decade
One of the report’s key findings is the sharp increase in pharmaceutical patent activity.
Between 2015 and 2024:
- Indian pharmaceutical patent families increased from around 716 to 2,995.
- India’s share of global pharmaceutical patents rose from 3–4% to nearly 10%.
The report attributes this growth to:
- Increased investment in research and development.
- Stronger collaboration between academia and industry.
- Government support for translational research.
- Expansion of biotechnology startups and innovation ecosystems.
Drug Discovery Pipeline Expands
India’s pharmaceutical innovation ecosystem is no longer limited to manufacturing generic medicines.
The report notes that:
- The innovation pipeline now includes 1,095 programmes across 195 companies.
- More than 10 novel drug assets have emerged over the past decade.
- The number of biotech startups has grown from roughly 1,500 to 2,400.
Several breakthrough therapies have strengthened India’s innovation credentials, including:
- BIRSA 101, India’s first indigenous CRISPR-based therapeutic.
- NexCAR19, an indigenous CAR-T cell therapy priced at a fraction of comparable international treatments.
Drivers of Innovation
| Growth Driver | Impact |
|---|---|
| Government Funding | Nearly $5 billion for early-stage and translational research |
| Faster Regulatory Reviews | Drug development timelines reduced to 60–120 days |
| Research Infrastructure | Expansion of innovation hubs such as Genome Valley and C-CAMP |
| Academia–Industry Collaboration | Accelerated commercialization of research |
Venture Capital Investment Accelerates
Investor confidence in India’s pharmaceutical innovation ecosystem is also strengthening.
According to the report:
- Private equity and venture capital investments increased 2.1 times over the past five years.
- Funding reached $731 million in FY26.
- Small-molecule therapeutics accounted for nearly 49% of PE/VC investments.
- AI and digital therapeutics attracted around 17% of private capital.
The report also points to high-profile global licensing agreements involving Indian companies as evidence of increasing international confidence in India-origin science.
Challenges Remain
Despite the strong progress, the report identifies several structural gaps that need to be addressed.
These include:
- India conducts only around 4% of global clinical trials, despite accounting for nearly 15% of the global disease burden.
- Annual pharmaceutical R&D spending remains at $2–3 billion, well below the $70–75 billion invested annually in the United States.
- Only 10–15% of Indian venture capital firms specialize in pharmaceutical and biotechnology investments, compared with roughly 60% in the US.
Addressing these gaps will be essential if India aims to become a global leader in life sciences innovation.
Why It Matters
India has long been recognized as the “pharmacy of the world” because of its leadership in generic medicines. The latest report suggests the country is now building capabilities in original drug discovery, advanced biotechnology, and precision medicine.
A stronger innovation ecosystem could:
- Increase high-value pharmaceutical exports.
- Attract greater foreign investment.
- Improve access to advanced therapies.
- Enhance India’s competitiveness in the global life sciences industry.
Looking Ahead
The BCG–HealthKois report indicates that India’s pharmaceutical industry is entering a new phase of innovation-led growth. With patent filings increasing fourfold, more than 10 novel drug molecules discovered, and the drug development pipeline expanding to over 1,000 programmes, the country is steadily moving beyond its traditional reliance on generic medicines. Rising venture capital investment, stronger government support, and improved research infrastructure are helping position India as an emerging hub for life sciences innovation.
Looking ahead, sustaining this momentum will require greater investment in clinical research, higher R&D spending, specialized biotech funding, and continued collaboration between industry, academia, and government. If these structural gaps are addressed, India could strengthen its position as a global center for pharmaceutical innovation and next-generation drug discovery over the coming decade.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
